Itraconazole

Evidence Level: L5

Predicted Indications: 1

Itraconazole

Pharmacist Assessment Report

Itraconazole: Pneumocystosis

One-Sentence Summary

Itraconazole is a triazole antifungal originally used for systemic fungal infections such as candidiasis, aspergillosis, histoplasmosis, blastomycosis and sporotrichosis. The prediction is best treated as a model signal rather than an evidence-backed lead.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Pneumocystosis
TxGNN Prediction Score	0.9934
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Itraconazole is a triazole antifungal; this class inhibits CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis in fungal cell membranes. This is general class knowledge rather than data from the compiled record.

For pneumocystosis, the mechanistic link is weak. Pneumocystis jirovecii is fungal, but its membrane contains very little ergosterol (cholesterol is the main sterol), so the azole target is poorly relevant. The retrieved literature consists of general reviews on prophylaxis in transplant, HIV and neutropenic populations and histoplasmosis papers; none shows itraconazole efficacy against Pneumocystis.

By contrast, the lower-ranked predictions are mechanistically more coherent, because the pathogens are ergosterol-containing fungi (see the table of other predictions in the Conclusion).

Clinical Trial Evidence

Currently no related clinical trials registered for pneumocystosis.

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00000639	NA	Completed	400	Amphotericin B with flucytosine vs amphotericin B alone in AIDS-associated cryptococcal meningitis, followed by a fluconazole vs itraconazole comparison
NCT00012467	Phase 2	Completed	60	Interferon-gamma 1b added to standard antifungal therapy; the agents in standard therapy cannot be confirmed from the truncated title

Literature Evidence

The most relevant publications retrieved for pneumocystosis are listed below. None demonstrates efficacy of itraconazole against Pneumocystis.

PMID	Year	Type	Journal	Key Findings
11737382	2001	Randomised placebo-controlled trial (Phase III)	HIV Medicine	Itraconazole capsules for prevention of deep fungal infections in immunodeficient HIV patients; the abstract excerpt does not report a Pneumocystis outcome
15250025	2004	Review	Clin Infect Dis	Antimicrobial prophylaxis in febrile neutropenia; trimethoprim-sulfamethoxazole is highly effective against Pneumocystis pneumonia
21418688	2010	Review	BMJ Clin Evid	Primary and secondary prophylaxis of opportunistic infections in HIV
21973267	2011	Review	Clin Pharmacokinet	Penetration of antifungal and other anti-infective agents into pulmonary epithelial lining fluid
2121456	1990	Review	Drugs	Therapy and prophylaxis of systemic protozoan infections, including Pneumocystis
8016481	1993	Review	Semin Respir Infect	Infection after lung transplantation
8397916	1993	Review	Curr Clin Top Infect Dis	Prophylaxis and treatment of infection in bone marrow transplant recipients
26036497	2015	Cohort	Transplant Proc	Invasive fungal infections after kidney transplantation
2233233	1990	Clinical review	Medicine	Disseminated histoplasmosis in AIDS
36891307	2023	Case report and review	Front Immunol	T. marneffei and P. jirovecii coinfection in a child with a STAT1 mutation

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 10732W	Lozanoc	Capsule 50 mg (oral)	Not available in the data compiled

Only one registered product was identified, and the identifier is as recorded in the data compiled for this report (it should be verified against the ARTG).

Safety Considerations

Safety text from the Australian Product Information was not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Disease associations flagged in the knowledge graph (not label text): long QT syndrome and torsades de pointes, congestive heart failure, cardiomyopathy and other myocardial disorders, coronary artery disease, liver disease and drug-induced liver injury, kidney disease, chronic obstructive pulmonary disease, peripheral neuropathy, hearing loss and vision disorders, and potassium deficiency. These should be verified against the PI.

Drug interactions (DDInter, 100 interactions recorded; selected examples):

Major: loperamide, triamcinolone, budesonide
Moderate: famotidine, ranitidine, cimetidine, omeprazole, rabeprazole, hydrocortisone, dexamethasone, betamethasone, alosetron, aprepitant
Minor: metformin, pioglitazone, chlorpropamide, amphotericin B

Itraconazole is a CYP3A4 inhibitor, so extensive interactions are expected. Acid-suppressing drugs can also reduce absorption of some formulations.

Conclusion and Next Steps

Decision: Hold

Rationale:

The top-ranked prediction, pneumocystosis, has no clinical trials and no supporting literature. It also has a weak mechanistic basis, because Pneumocystis has little ergosterol. Evidence level is L5.
The score appears to reflect the drug’s antifungal class rather than a real therapeutic signal.

Other predictions in the data compiled:

| Rank | Predicted Indication | Score | Evidence Level | Assessment | |——|——|——|——|——|

To proceed, the following is needed:

Verification of the intervention arms in NCT00012467 and NCT00000639
The Australian PI warnings, contraindications and approved indication text for ARTG 10732W
A cardiac, hepatic and drug-interaction risk assessment before any new use is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.